Camber Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Camber Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500,000	Closed	-$12.6M	–	50
2022 Q3	$12.6M	Sell	500,000 -1,000,000	-67%	-$27.7M	0.38%	43
2022 Q2	$45.6M	Hold	1,500,000	–	–	1.98%	17
2022 Q1	$49.1M	Buy	+1,500,000	New	+$44.5M	1.78%	20
2021 Q4	–	Sell	-685,000	Closed	-$68.9M	–	44
2021 Q3	$68.9M	Buy	685,000 +220,000	+47%	+$25.8M	2.12%	24
2021 Q2	$65.8M	Buy	465,000 +65,000	+16%	+$7.34M	2.22%	22
2021 Q1	$39.9M	Buy	+400,000	New	+$46.7M	1.37%	25

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Camber Capital Management's RETA Position: Q4 2022 in Review

Camber Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 500,000 shares — an estimated $12.6M sold.

Camber Capital Management first reported a position in RETA in Q1 2021 and held it in 6 quarters. The position peaked at $68.9M in Q3 2021. 167 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

Camber Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Camber Capital Management sold 500,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $12.6M.
Camber Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 6 quarters.
Camber Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $68.9M in Q3 2021.
167 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Camber Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.